Optimizing Lipid Lowering Therapy in Women: Gaps Perspectives and Advances
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Click Here to Manage Email Alerts
This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Program Overview:
Release Date: November 9, 2022
Expiration Date: November 9, 2023
Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally. Even with advances in LDL-C (low-density lipoprotein cholesterol) lowering therapy, LDL-C goal achievement in high-risk women is lower than that in men, with clinical inertia, statin intolerance, and non-adherence being major factors for continued ASCVD residual risk. The landscape of LDL-C lowering therapy is rapidly evolving, with several new and emerging agents that may help address these gaps, and now the options for combination therapy go beyond what is in the guidelines.
In this symposium from the 2022 Women’s Cardiometabolic Health and Wellness Masterclass, faculty will discuss and offer their perspectives on how to optimize and integrate these agents into standard of care, and optimize LDL-C lowering therapy in women.
Instructions for Participation
In order to receive credit, participants must complete the activity in its entirety. Participants must also score at least an 80% on the posttest and submit it, along with the credit application and evaluation form.
There are no fees for participating in this activity.
For additional information about the accreditation of this activity, please visit https://partnersed.com
Learning Objectives:
After completing this activity, the participant should be better able to:
- Recognize the burden of ASCVD risk in women, and challenges with optimizing statin therapy
- Explain the need for the early and adequate intensification of LDL-C lowering therapy beyond statins in women to address ASCVD risk.
- Summarize the efficacy and safety of PCSK9 inhibitors across trial and real-world studies.
- Discuss the rationale, efficacy, and safety of novel LDL-C lowering agents and their potential impact in addressing current gaps in lipid-lowering therapy in women.
- Select individualized treatment strategies to optimize lipid-lowering therapy in women that prioritize the early initiation and intensification of therapy to reduce ASCVD risk.
Chair
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Director of Women's Cardiovascular Health
Associate Professor of Medicine
Johns Hopkins Medicine
Baltimore, MD
Dr. Michos discloses the following:
Consultant, Advisor, Speaker: AstraZeneca, Bayer, Boehringer Ingelheim, Esperion, Novartis, Novo Nordisk, Pfizer
Faculty
Christie M. Ballantyne, MD
Professor of Medicine, Baylor College of Medicine
Houston, TX
Dr. Ballantyne discloses the following:
Grant/Research Support: (All paid to institution, not individual): Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, lonis, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, NIH, AHA, ADA.
Consultant: 89Bio, Abbott Diagnostics, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Gilead, lllumina, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Heather M. Johnson, MD, MS, MMM, FAHA, FACC, FASPC
Preventive Cardiologist/Cardiologist
Lynn Women’s Health & Wellness Institute/Baptist Health
South Florida
Boca Raton, FL
Dr. Johnson discloses the following:
Consultant, Advisor, Speaker: American Society of Preventive Cardiology Researcher: NIH/NHLBI
Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC
Director, Preventive Cardiology
Associate Director, Barbra Streisand Women’s Heart Center, Cedars- Sinai Heart Institute
Los Angeles, CA
Dr. Gulati has nothing to disclose.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-22-236-H01-P. Type of activity: Knowledge
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DISCLOSURES
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The CMHC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
DISCLOSURE OF CONFLICT OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.